{
  "docId": "019de074-1cfe-7508-8ae3-4ba4db03f42e",
  "docSlug": "98d74dc525a4b13d13a1ee51c3af4583",
  "documentTitle": "Kymera | Results Presentation Deck | 63 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 63,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-1cfe-7508-8ae3-4ba4db03f42e/4",
  "deckHref": "/decks/019de074-1cfe-7508-8ae3-4ba4db03f42e",
  "deckJsonHref": "/decks/019de074-1cfe-7508-8ae3-4ba4db03f42e.json",
  "deckAnchorHref": "/decks/019de074-1cfe-7508-8ae3-4ba4db03f42e#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.62,
        "x": 0.35,
        "y": 0.21
      },
      "kind": "list",
      "text": "Key accomplishments to date: Since 2016 founding, advanced 4 clinical stage programs and developed a deep pipeline positioned to deliver ≥1 IND/year. Unique target selection strategy based on using TPD to unlock high value, undrugged targets. First to advance degraders (KT-474) in healthy volunteers and patients with HS and AD, demonstrating degrader vs. small molecule inhibitors (SMI) biological differentiation, and potential best in class profile in I/I. Demonstrated fidelity of translation of PK, PD and safety across three clinical programs in I/I and oncology patients. Well capitalized with $596 million of cash as of 9/30/22 positioning Kymera to accelerate and expand clinical impact in areas with large clinical and commercial opportunities.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de4f61d7-be33-43b3-b522-6e47bc96f53e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.03,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "Kymera is a leader in Targeted Protein Degradation (TPD). Building a fully-integrated, global biotech company. Initial focus in Immunology/Inflammation and Oncology, but already a disease-agnostic platform. Accelerating forward integration through key strategic partnerships.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8dfa442d-e8e7-4299-941d-cd5908792471",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.32,
        "x": 0.34,
        "y": 0.04
      },
      "kind": "title",
      "text": "Introduction to Kymera",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5cd1d73c-d938-44f6-8ddd-b82d9f3ee5f0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 4,
      "from": 1,
      "beatId": "772418fa-5a0b-47b3-9a75-a3068550e8af",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem Identification",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "Introduction to Kymera and pipeline overview",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}